|
|
Taiwan Academic Institutional Repository >
Browse by Author
|
"kudo m"
Showing items 46-55 of 76 (8 Page(s) Totally)
<< < 1 2 3 4 5 6 7 8 > >>
View [10|25|50] records per page
| 臺大學術典藏 |
2021-02-18T08:01:11Z |
The AFSUMB consensus statements and recommendations for the clinical practice of contrast-enhanced ultrasound using sonazoid
|
Lee J.Y.; Minami Y.; Choi B.I.; Lee W.J.; Chou Y.-H.; Jeong W.K.; Park M.-S.; Kudo N.; Lee M.W.; Kamata K.; Iijima H.; Kim S.Y.; Numata K.; Sugimoto K.; Maruyama H.; Sumino Y.; Ogawa C.; Kitano M.; Joo I.; Arita J.; JA-DER LIANG; Lin H.-M.; Nolsoe C.; Gilja O.H.; Kudo M. |
| 臺大學術典藏 |
2021-02-18T02:09:13Z |
Corrigendum to Nivolumab in advanced hepatocellular carcinoma: Sorafenib-experienced Asian cohort analysis
|
Yau T.;Chiun Hsu;Kim T.-Y.;Choo S.-P.;Kang Y.-K.;Hou M.-M.;Numata K.;Yeo W.;Chopra A.;Ikeda M.;Kuromatsu R.;Moriguchi M.;Chao Y.;Zhao H.;Anderson J.;Dela Cruz C.;Kudo M.; Yau T.; Chiun Hsu; Kim T.-Y.; Choo S.-P.; Kang Y.-K.; Hou M.-M.; Numata K.; Yeo W.; Chopra A.; Ikeda M.; Kuromatsu R.; Moriguchi M.; Chao Y.; Zhao H.; Anderson J.; Dela Cruz C.; Kudo M. |
| 臺大學術典藏 |
2021-02-18T02:09:12Z |
Efficacy and Safety of Nivolumab plus Ipilimumab in Patients with Advanced Hepatocellular Carcinoma Previously Treated with Sorafenib: The CheckMate 040 Randomized Clinical Trial
|
Yau T.;Kang Y.-K.;Kim T.-Y.;El-Khoueiry A.B.;Santoro A.;Sangro B.;Melero I.;Kudo M.;Hou M.-M.;Matilla A.;Tovoli F.;Knox J.J.;Ruth He A.;El-Rayes B.F.;Acosta-Rivera M.;Lim H.-Y.;Neely J.;Shen Y.;Wisniewski T.;Anderson J.;Chiun Hsu; Yau T.; Kang Y.-K.; Kim T.-Y.; El-Khoueiry A.B.; Santoro A.; Sangro B.; Melero I.; Kudo M.; Hou M.-M.; Matilla A.; Tovoli F.; Knox J.J.; Ruth He A.; El-Rayes B.F.; Acosta-Rivera M.; Lim H.-Y.; Neely J.; Shen Y.; Wisniewski T.; Anderson J.; Chiun Hsu |
| 臺大學術典藏 |
2021-02-18T02:09:11Z |
Challenges of combination therapy with immune checkpoint inhibitors for hepatocellular carcinoma
|
Cheng A.-L.;Chiun Hsu;Chan S.L.;Choo S.-P.;Kudo M.; Cheng A.-L.; Chiun Hsu; Chan S.L.; Choo S.-P.; Kudo M. |
| 國立成功大學 |
2021 |
Effect of ramucirumab on ALBI grade in patients with advanced HCC: Results from REACH and REACH-2
|
Kudo, M.;Galle, P.R.;Brandi, G.;Kang, Y.-K.;Yen, C.-J.;Finn, R.S.;Llovet, J.M.;Assenat, E.;Merle, P.;Chan, S.L.;Palmer, D.H.;Ikeda, M.;Yamashita, T.;Vogel, A.;Huang, Y.-H.;Abada, P.B.;Yoshikawa, R.;Shinozaki, K.;Wang, C.;Widau, R.C.;Zhu, A.X. |
| 國立成功大學 |
2021 |
Ramucirumab for patients with intermediate-stage hepatocellular carcinoma and elevated alpha-fetoprotein: Pooled results from two phase 3 studies (REACH and REACH-2)
|
Kudo, M.;Finn, R.S.;Morimoto, Morimoto M.;Rau, K.-M.;Ikeda, M.;Yen, C.-J.;Galle, P.R.;Llovet, J.M.;Daniele, B.;Lim, H.Y.;McIlwain, D.W.;Yoshikawa, R.;Nakamura, K.;Liang, K.;Wang, C.;Abada, P.;Widau, R.C.;Zhu, A.X. |
| 國立成功大學 |
2021 |
Serum alpha-fetoprotein and clinical outcomes in patients with advanced hepatocellular carcinoma treated with ramucirumab
|
Zhu, A.X.;Finn, R.S.;Kang, Y.-K.;Yen, C.-J.;Galle, P.R.;Llovet, J.M.;Assenat, E.;Brandi, G.;Motomura, K.;Ohno, I.;Daniele, B.;Vogel, A.;Yamashita, T.;Hsu, C.-H.;Gerken, Gerken G.;Bilbruck, J.;Hsu, Y.;Liang, K.;Widau, R.C.;Wang, C.;Abada, P.;Kudo, M. |
| 國家衛生研究院 |
2020-09 |
Long-term follow-up of bintrafusp alfa, a bifunctional fusion protein targeting TGF-beta and PD-L1, in patients with pretreated biliary tract cancer
|
Yoo, C;Oh, DY;Choi, HJ;Kudo, M;Ueno, M;Kondo, S;Chen, LT;Osada, M;Helwig, C;Dussault, I;Ikeda, M |
| 臺大學術典藏 |
2020-08-13T06:33:32Z |
Ramucirumab safety in East Asian patients: A meta-analysis of six global, randomized, double-blind, placebo-controlled, phase III clinical trials
|
Zhang Y.; Sohn J.; Cheng R.; Yamazaki K.; Kim S.-W.; Chao Y.; Lee K.-W.; JIN-YUAN SHIH; Kudo M.; Kim T.-W.; Muro K.; Yen C.-J.; Yen C.-J.;Muro K.;Kim T.-W.;Kudo M.;Jin-Yuan Shih;Lee K.-W.;Chao Y.;Kim S.-W.;Yamazaki K.;Sohn J.;Cheng R.;Zhang Y.;Binder P.;Mi G.;Orlando M.;Chung H.C.; Binder P.; Mi G.; Orlando M.; Chung H.C. |
| 臺大學術典藏 |
2020-08-11T08:36:43Z |
Orantinib versus placebo combined with transcatheter arterial chemoembolisation in patients with unresectable hepatocellular carcinoma (ORIENTAL): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study
|
Kudo M.;Cheng A.-L.;Park J.-W.;Park J.H.;Po-Chin Liang;Hidaka H.;Izumi N.;Heo J.;Lee Y.J.;Sheen I.-S.;Chiu C.-F.;Arioka H.;Morita S.;Arai Y.; Kudo M.; Cheng A.-L.; Park J.-W.; Park J.H.; PO-CHIN LIANG; Hidaka H.; Izumi N.; Heo J.; Lee Y.J.; Sheen I.-S.; Chiu C.-F.; Arioka H.; Morita S.; Arai Y. |
Showing items 46-55 of 76 (8 Page(s) Totally)
<< < 1 2 3 4 5 6 7 8 > >>
View [10|25|50] records per page
|
